Harmony Biosciences (HRMY) Tops Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Harmony Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
February 28, 2022 7:30 AM ESTWAKIX® (pitolisant) Net Revenue Increased 62% Year-over-Year to $91.2 Million for Fourth Quarter 2021 and 91% to $305.4 Million for Full Year
Achieved First Full Year of Profitability and Net income was $22.7 Million for the Fourth Quarter 2021
Average Number of Patients on WAKIX Increased to ~3,800
On Track to Initiate the Phase 3 Clinical Trial in Patients with Idiopathic Hypersomnia First Half of This Year
 Year-End 2021 Cash and Cash Equivalents of Approximately $234 Million
Conference Call and Webcast to be Held Today at 8:30 a.m. ETÂ
... More